<DOC>
	<DOC>NCT01103024</DOC>
	<brief_summary>The purpose of the extension study is to provide patients completing the 28-week core study with an opportunity to receive an additional 22 weeks of continuous treatment.</brief_summary>
	<brief_title>Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<criteria>Patients who have completed the entire treatment period of the 28week core study Patients must be able to understand and communicate with the investigator and comply with the requirements for the study and must give a written, signed, and dated informed consent before study treatment in the extension study Inability or unwillingness to undergo repeated subcutaneous injections Inability to comply with study or followup procedures Any medical or psychiatric condition which, in the investigator's opinion would preclude the participant from adhering to the protocol or completing the study per protocol Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (&gt; 5 mIU/mL) Women of childbearing potential (WoCBP), defined as all women physiologically capable of becoming pregnant, UNLESS They are using simultaneously double barrier or two acceptable methods of contraception They are postmenopausal with an appropriate clinical profile and had no regular menstrual bleeding for at least twelve (12) months prior to initial dosing They have undergone reliable surgical sterilization at least six (6) months prior to initial dosing Their career, lifestyle, or sexual orientation precludes intercourse with a male partner Partners have been sterilized by vasectomy or other reliable means Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Active uveitis</keyword>
	<keyword>intermediate uveitis</keyword>
	<keyword>panuveitis</keyword>
	<keyword>posterior uveitis</keyword>
	<keyword>uveitis</keyword>
</DOC>